Press Releases

May 1, 2023 || Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
BOSTON, May 1, 2023 – Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that interim data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster discussion presentation at the upcoming 2023 American Society […] » Read more
April 27, 2023 || Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors
The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors, potentially defeating resistance mechanisms » Read more
January 17, 2023 || Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology » Read more
October 4, 2022 || Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology (MIT), demonstrating Elicio’s Amphiphile (AMP) platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization. » Read more
September 20, 2022 || Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations » Read more
September 7, 2022 || Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine Against SARS-CoV-2
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants […] » Read more
July 6, 2022 || Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications
Data showed that vaccination with AMP-CpG combined with EBV gp350 and EBVpoly proteins delivered directly to the lymph nodes rapidly induced potent gp350-specific antibodies (IgG), EBV neutralizing antibody responses and EBV-specific T cell responses in HLA transgenic mice. » Read more
July 6, 2022 || Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications
The presented data show ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in mice. » Read more
May 27, 2022 || Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in mutant KRAS-Driven Cancers at ASCO Annual Meeting 2022
AMPLIFY-201 is a Phase 1 clinical study of ELI-002, a lymph node-targeted therapeutic cancer vaccine, in patients with mKRAS-driven cancers; the first patient was dosed at MD Anderson » Read more
May 23, 2022 || Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors
Data published in bioRxiv shows AMP-vaccination significantly enhanced TCR-T cell anti-tumor response, while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid tumors in an established, syngeneic tumor model » Read more
May 16, 2022 || Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC) » Read more
May 12, 2022 || Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
BOSTON, May 12, 2022 – Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and the promotion of Dr. Peter DeMuth to Chief Scientific Officer. Ms. Seymour will oversee the […] » Read more
April 29, 2022 || Elicio Therapeutics Presents Preclinical Data on the AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy for Solid Tumors at the 2022 Keystone Symposia: Emerging Cellular Therapies
Data shows that AMP-vaccination significantly enhanced TCR-T cell anti-tumor response while also inducing epitope spread among the endogenous T cell population, leading to durable cures of solid tumors in an established, syngeneic tumor model AMP-vaccination delivers cognate peptides and adjuvant to lymph nodes which induces dendritic cell activation and provides in vivo activation of tumor-specific […] » Read more
March 29, 2022 || Elicio Therapeutics Presents Updated Preclinical Data at Vaccines Summit Boston 2022 on ELI-005, a Lymph Node-Targeted Amphiphile Vaccine, Demonstrating It Induces Potent Cross-Reactive Cellular and Humoral Immunity to SARS-CoV-2
ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates » Read more
March 23, 2022 || Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event
AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence » Read more
March 15, 2022 || Elicio Therapeutics Moves into Boston’s Seaport District and Provides Update on Programs
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced its move from Cambridge, MA to a larger facility in Boston’s Seaport District and an update on its programs for 2022. » Read more
November 12, 2021 || Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting
Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model » Read more
October 6, 2021 || Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers
The first patient was dosed at MD Anderson as part of a multicenter clinical trial to evaluate the safety and efficacy of ELI-002, an investigational lymph node-targeted therapeutic vaccine, in patients with KRAS-driven tumors. » Read more
September 22, 2021 || Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit, being held virtually on September 20-22, 2021. » Read more
September 17, 2021 || Elicio Therapeutics Announces Virtual Presentation of Data on its Amphiphile-CpG Adjuvant at the Vaccines Summit 2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that it will present preclinical data on its AMP-CpG adjuvant (AMP-CpG) at the Vaccines Summit 2021, being held virtually from September 20-22, 2021 » Read more
September 10, 2021 || Elicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the initiation of AMPLIFY-201, a Phase 1/2 dose-escalation study evaluating the safety and preliminary efficacy of ELI-002, the Company’s therapeutic vaccine that is being investigated as a potential treatment for patients with KRAS-driven tumors who have minimal residual disease following surgical tumor resection. » Read more
June 29, 2021 || Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers
Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the initiation of AMPLIFY-201, a Phase 1/2 dose-escalation study evaluating the safety and preliminary efficacy of ELI-002, the Company’s therapeutic vaccine that is being investigated as a potential treatment for patients with KRAS-driven tumors who have minimal residual disease following surgical tumor resection. » Read more
February 23, 2021 || Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002– A Therapeutic Vaccine Targeting mutated KRAS Cancers
CAMBRIDGE MA., February 23, 2021 – Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for ELI-002. ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG adjuvant, administered subcutaneously. » Read more
February 17, 2021 || Elicio Therapeutics Secures a Total of $73 Million in Series B Financing
CAMBRIDGE MA., February 17, 2021 – Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced the successful completion of Series B financing bringing the total funds raised in the current round to $73 million. Elicio funding has been established from an international investor base, including multiple strategic and institutional investors » Read more
February 15, 2021 || Elicio Therapeutics to discuss success of Amphiphiles enabled T cell therapies at CAR-TCR Digital Summit Europe
CAMBRIDGE MA., FEBRUARY 15, 2021 (BusinessWire) – Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, today announced Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer, will co-lead a workshop, “Improving Efficacy and Solid Tumor Infiltration with Combination […] » Read more
February 5, 2021 || Elicio Therapeutics’ SARS CoV-2 vaccine demonstrates T Cell responses >25 fold higher than benchmark vaccines Preclinical data published in Science Advances
A proprietary lymph node targeting adjuvant for COVID-19 has elicited high magnitude T cell responses alongside potent neutralizing antibody induction; the studies are published in the February 5 issue of Science Advances. Significantly, the magnitude of T cell responses substantially exceeded prior observations in mouse models with benchmark COVID-19 vaccines. ELI-005, Elicio Therapeutics’ novel SARS-CoV-2 vaccine, […] » Read more
February 2, 2021 || Annette Matthies, PH.D., Joins Elicio Therapeutics as Chief Business Officer
Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, announced today that Annette Matthies, Ph.D., has joined as Chief Business Officer. At Elicio, she will lead all business and corporate development efforts, including acquisitions, licensing agreements, partnerships, and portfolio management. » Read more
November 11, 2020 || Elicio Announces Additions to Board of Directors
Elicio Therapeutics, a next generation immunotherapy company, has named Daphne Karydas, Chief Financial Officer at Syndax Pharmaceuticals and Carol Ashe, Chief Business Officer at the New York Genome Center, to its board of directors.   » Read more
November 10, 2020 || Elicio Therapeutics Announces Poster Presentation at 2020 Society for Immunotherapy of Cancer Annual Meeting
Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity. » Read more
November 5, 2020 || Elicio Therapeutics VP of Research and Founding Scientist talk COVID19
We are thrilled to feature our VP of Research Pete DeMuth, and Elicio’s Founding Scientist Darrell Irvine, as a guest on Julian Adams, CEO of Gamida Cell, new podcast “Science Side by Side” where they discuss the development, approval and delivery of a vaccine to prevent #COVID19. » Read more
September 17, 2020 || Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T cells
Elicio Therapeutics, a next generation immuno-oncology company, today announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells. » Read more
August 19, 2020 || Lymph node targeting COVID-19 vaccine induces up to 25-fold more T cells over benchmark vaccines and >265-fold greater antibody levels than recovering patients
Preclinical data from a lymph node targeted COVID-19 vaccine candidate showed potent CD8 and CD4 T Cells in lung tissue and respiratory fluid » Read more
June 22, 2020 || Adrian Bot, MD, PhD, Named to Elicio Therapeutics Scientific Advisory Board
Elicio Therapeutics, a next generation immuno-oncology company, announced today that Adrian Bot, MD, PhD, Vice President of Translational Medicine at Kite, a Gilead Company, has joined Elicio’s Scientific Advisory Board. » Read more
April 16, 2020 || Elicio Therapeutics and National Cancer Institute Collaborate to Study ELI-002 mutant KRAS Targeting Mechanism
Elicio Therapeutics, a next generation immuno-oncology company, today announced that it has established a collaboration with the National Cancer Institute (NCI) to characterize T cell responses to ELI-002 in animals. » Read more
April 15, 2020 || Esther Welkowsky Joins Elicio Therapeutics as Vice President Clinical Operations
Esther Welkowsky, an accomplished clinical operations leader with over 15 years of biotechnology development experience across T cell immunotherapy, biologics, and small molecules, Will lead Elicio’s oversee clinical operations and assist in defining development strategy, guiding protocol design, study conduct, and regulatory compliance. » Read more
February 19, 2020 || Elicio Therapeutics to discuss novel lymph node vaccine targeting seven key mKRAS mutations at RAS – Targeted Drug Discovery Summit in Vienna, Austria
Elicio Therapeutics, a next generation immuno-oncology company, today announced Peter DeMuth, PhD., Elicio Vice President of Research, will present “Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses,” at the upcoming RAS-Targeted Drug Discovery Summit in Vienna, Austria, from February 25 to 27, 2020. » Read more
February 12, 2020 || Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002
Elicio Therapeutics and Natera, Inc.(NASDAQ: NTRA) today announced their collaboration in a prospective, multicenter Phase 1/2 study of ELI-002, an Amphiphile immuno-oncology therapeutic targeting KRAS mutations in the adjuvant setting for patients with pancreatic ductal adenocarcinoma (PDAC) who have undergone neoadjuvant chemotherapy followed by pancreatectomy. IND submission for the 108-patient trial which will open at 10-12 US sites will be in the first half of 2020. » Read more
October 25, 2019 || FIERCE BIOTECH: Chutes and Ladders
Cambridge, Massachusetts-based Elicio Therapeutics has hired Christopher Haqq, M.D., Ph.D., as CMO and executive vice president and head of R&D. Haqq was the first employee and CMO of Atara Biotherapeutics, and later its CSO. » Read more
October 23, 2019 || Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head
Will lead Elicio’s transition to clinical-stage and oversee, prioritize and advance the company’s rich pipeline of immunotherapies. » Read more
October 2, 2019 || Elicio Therapeutics Completes $33 Million Series B Financing
Proceeds will advance Elicio’s pipeline including an Amphiphile Vaccine targeting mKRAS-Driven Cancers. CAMBRIDGE MA., October 2nd, 2019 (BusinessWire) – Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing. » Read more
August 7, 2019 || Elicio Therapeutics Presents In Vivo Data for a Universal Amphiphile Vaccine Targeting KRAS-Driven Cancers
Demonstrates robust immune responses and cytolytic activity targeting the seven key mKRAS mutations CAMBRIDGE MA., AUGUST 7th, 2019 (BusinessWire) – Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019. Now, Elicio Therapeutics, a next generation immuno-oncology company, is presenting significant preclinical data from a novel lymph-node […] » Read more
July 11, 2019 || Elicio Therapeutics Co-founder, Darrell Irvine, Co-authors Research Published in Science Demonstrating Novel AMP-CAR-T Approach to Enhance CAR-T Function in Solid Tumor Cancers
Elicio Therapeutics today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response. » Read more
July 11, 2019 || BioCentury: Elicio’s cancer vaccine boosts CAR Ts for solid tumors
Elicio Therapeutics (Cambridge, Mass.), which launched in March, exclusively licensed the platform, Amphiphile, from co-founder Darrell Irvine at the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology. » Read more
March 27, 2019 || Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers
$30 Million Financing Backing MIT-Developed Amphiphile Platform to Target a Wide-Range of Immunogens to the Lymph Nodes, the “Brain Center’ of the Immune Response CAMBRIDGE MA., March 27, 2019 (BusinessWire) – Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today and announced the appointment of Robert Connelly as […] » Read more